Zinc and tetrathiomolybdate for the treatment of Wilson's disease and the potential efficacy of anticopper therapy in a wide variety of diseases

Metallomics

Volumn 1, Issue 3, 2009, Pages 199-206

  Brewer, George J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOIMMUNE DISORDER; CELLULAR UPTAKE; CERULOPLASMINS; COPPER ACCUMULATION; COPPER TOXICITY; COVALENTLY BOUND; CYTOKINES; DISEASE PROCESS; POTENTIAL EFFICACY; SMALL MOLECULES; TETRATHIOMOLYBDATE; WILSON'S DISEASE;

BIOSYNTHESIS; BLOOD; COPPER; DRUG THERAPY; LAKES; TOXICITY; ZINC;

DISEASE CONTROL;

ALBUMIN; CERULOPLASMIN; COPPER; CYTOKINE; PENICILLAMINE; TETRATHIOMOLYBDIC ACID; TRIENTINE; ZINC;

AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; AUTOSOMAL RECESSIVE DISORDER; CHEMICAL BOND; COPPER BLOOD LEVEL; DISEASE COURSE; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; FIBROSIS; GASTROINTESTINAL SYMPTOM; HUMAN; LEUKOPENIA; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT DURATION; WILSON DISEASE;

CHELATING AGENTS; COPPER; HEPATOLENTICULAR DEGENERATION; HUMANS; MOLYBDENUM; ZINC;

LYCAENINAE;

EID: 77953495477     PISSN: 17565901     EISSN: 1756591X     Source Type: Journal    
DOI: 10.1039/b901614g     Document Type: Review

References (76)

1. G. J. Brewer, Wilson's Disease: A Clinician's Guide to Recognition, Diagnosis, and Management, Kluwer Academic Publishers, Boston, MA, 2001
2. G. J. Brewer, Wilson's Disease, in Harrison's Principles of Internal Medicine, ed., A. S. Fauci,,, E. Braunward,,, D. L. Kasper,,, S. L. Hauser,,, D. L. Longo,,, J. L. Jameson, and, J. Loscalzo,, McGraw-Hill Companies, Inc, New York, NY, 2008, pp. 2449-2452
3. G. J. Brewer Recognition, diagnosis, and management of Wilson's disease Exp. Biol. Med. 2000 223 39 46
4. G. J. Brewer V. Yuzbasiyan-Gurkan Wilson disease Medicine 1992 71 139 164
5. I. H. Scheinberg and I. Sternlieb, Wilson's disease, in Major Problems in Internal Medicine, ed., L. H. J. Smith,, W.B. Saunders Company, Philadelphia, 1984, pp. 1-171
6. M. L. Schilsky Wilson disease: genetic basis of copper toxicity and natural history Semin. Liver Dis. 1996 16 83 95
7. S. A. Wilson Progressive lenticular degeneration: A familial nervous disease associated with cirrhosis of the liver Brain 1912 34 295 507
8. A. Rumpel Ueber das wesen un die bedeutung der leberveränderungen und der pigmentierunen bei den damit verbundenen fällen von pseudosklerose, zugleich ein beitrag zur lehre von pseudosklerose (Westphal-Strümpell) Dtsch. Z. Nervenheilkd. 1913 49 54 73
9. J. N. Cumings The copper and iron content of brain and liver in the normal and in hepato-lenticular degeneration Brain 1948 71 410 415
10. B. M. Mandelbrote M. W. Stanier R. H. S. Thompson M. N. Thurston Studies on copper metabolism in demyelinating diseases of the central nervous system Brain 1948 71 212 228
11. A. H. Ravestyn Metabolism of copper in man Acta Med. Scand. 1944 118 163 196
12. D. J. Frommer Defective biliary excretion of copper in Wilson's disease Gut 1974 15 125 129
13. P. C. Bull G. R. Thomas J. M. Rommens J. R. Forbes D. W. Cox The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene Nat. Genet. 1993 5 327 337
14. R. E. Tanzi K. Petrukhin I. Chernov J. L. Pellequer W. Wasco B. Ross D. M. Romano E. Parano L. Pavone L. M. Brzustowicz M. Devoto J. Peppercorn A. I. Bush I. Sternlieb M. Pirastu J. F. Gusella O. Evgrafov G. K. Penchaszadeh B. Honig I. S. Edelman M. B. Soare I. H. Scheinberg T. C. Gilliam The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene Nat. Genet. 1993 5 344 350
15. Y. Yamaguchi M. E. Heiny J. D. Gitlin Isolation and characterization of a human liver cDNA as a candidate gene for Wilson disease Biochem. Biophys. Res. Commun. 1993 197 271 277
16. D. W. Cox and E. Roberts, Wilson Disease, http://www.geneclinics.org/ profiles/wilson/details.html, accessed November 22, 2006
17. J. K. Fink P. Hedera G. J. Brewer Hepatolenticular degeneration (Wilson's disease) Neurologist 1999 5 171 185
18. G. J. Brewer, Behavioral Abnormalities in Wilson's Disease, in Behavioral Neurology of Movement Disorders, ed., W. J. Weiner,,, A. E. Lang, and, K. E. Anderson,,, Lippincott,, Williams & Wilkins, Philadelphia, 2005, pp. 262-274
19. G. J. Brewer V. Yuzbasiyan-Gurkan R. Dick Y. Wang V. Johnson Does a vegetarian diet control Wilson's disease? J. Am. Coll. Nutr. 1993 12 527 530
20. J. M. Walshe Penicillamine, a new oral therapy for Wilson's disease Am. J. Med. 1956 21 487 495
21. G. J. Brewer C. A. Terry A. M. Aisen G. M. Hill Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy Arch. Neurol. 1987 44 490 493
22. J. M. Walshe Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride Lancet 1982 1 643 647
23. G. J. Brewer F. Askari M. T. Lorincz M. Carlson M. Schilsky K. J. Kluin P. Hedera P. Moretti J. K. Fink R. Tankanow R. B. Dick J. Sitterly Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease Arch. Neurol. 2006 63 521 527
24. G. Schouwink, De hepatocerebrale degeneratie, me een onderzoek naar de zinktofwisseling, MD Thesis, University of Amsterdam, 1961
25. T. U. Hoogenraad C. J. Van den Hamer J. Van Hattum Effective treatment of Wilson's disease with oral zinc sulfate: two case reports Br. Med. J. 1984 289 273 276
26. T. U. Hoogenraad J. Van Hattum C. J. A. Van den Hamer Management of Wilson's disease with zinc sulfate. Experience in a series of 27 patients J. Neurol. Sci. 1987 77 137 146
27. G. J. Brewer, E. B. Schoomaker, D. A. Leichtman, W. C. Kruckleberg, L. F. Brewer and N. Myers, The Uses of Pharmacologic Doses of Zinc in the Treatment of Sickle Cell Anemia, in Zinc Metabolism: Current Aspects in Health and Disease, ed., G. J. Brewer, and, A. S. Prasad,, Allan R. Liss. Inc., New York, 1977, pp. 241-258
28. G. M. Hill G. J. Brewer A. S. Prasad C. R. Hydrick D. E. Hartmann Treatment of Wilson's disease with zinc. I. Oral zinc therapy regimens Hepatology 1987 7 522 528
29. G. M. Hill G. J. Brewer J. E. Juni A. S. Prasad R. D. Dick Treatment of Wilson's disease with zinc. II. Validation of oral 64copper with copper balance Am. J. Med. Sci. 1986 292 344 349
30. G. J. Brewer G. M. Hill R. D. Dick T. T. Nostrant J. S. Sams J. J. Wells A. S. Prasad Treatment of Wilson's disease with zinc: III. Prevention of reaccumulation of hepatic copper J. Lab. Clin. Med. 1987 109 526 531
31. G. J. Brewer G. Hill A. Prasad R. Dick The treatment of Wilson's disease with zinc. IV. Efficacy monitoring using urine and plasma copper Proc. Soc. Exp. Biol. Med. 1987 184 446 455
32. V. Yuzbasiyan-Gurkan G. J. Brewer G. D. Abrams B. Main D. Giacherio Treatment of Wilson's disease with zinc. V. Changes in serum levels of lipase, amylase, and alkaline phosphatase in patients with Wilson's disease J. Lab. Clin. Med. 1989 114 520 526
33. G. J. Brewer V. Yuzbasiyan-Gurkan D. Y. Lee H. Appelman Treatment of Wilson's disease with zinc. VI. Initial treatment studies J. Lab. Clin. Med. 1989 114 633 638
34. D. Y. Lee G. J. Brewer Y. X. Wang Treatment of Wilson's disease with zinc. VII. Protection of the liver from copper toxicity by zinc-induced metallothionein in a rat model J. Lab. Clin. Med. 1989 114 639 645
35. G. J. Brewer V. Yuzbasiyan-Gurkan R. Dick Zinc therapy of Wilson's disease: VIII. Dose response studies J. Trace Elem. Exp. Med. 1990 3 227 234
36. G. J. Brewer V. Yuzbasiyan-Gurkan V. Johnson Treatment of Wilson's disease with zinc. IX: Response of serum lipids J. Lab. Clin. Med. 1991 118 466 470
37. V. Yuzbasiyan-Gurkan A. Grider T. Nostrant R. J. Cousins G. J. Brewer Treatment of Wilson's disease with zinc: X. Intestinal metallothionein induction J. Lab. Clin. Med. 1992 120 380 386
38. G. J. Brewer V. Yuzbasiyan-Gurkan V. Johnson R. D. Dick Y. Wang Treatment of Wilson's disease with zinc: XI. Interaction with other anticopper agents J. Am. Coll. Nutr. 1993 12 26 30 (Pubitemid 23060169)
39. G. J. Brewer V. Yuzbasiyan-Gurkan V. Johnson R. D. Dick Y. Wang Treatment of Wilson's disease with zinc XII: Dose regimen requirements Am. J. Med. Sci. 1993 305 199 202
40. G. J. Brewer R. D. Dick V. Yuzbasiyan-Gurkan V. Johnson Y. Wang Treatment of Wilson's disease with zinc. XIII: Therapy with zinc in presymptomatic patients from the time of diagnosis J. Lab. Clin. Med. 1994 123 849 858
41. G. J. Brewer V. Johnson J. Kaplan Treatment of Wilson's disease with zinc: XIV. Studies of the effect of zinc on lymphocyte function J. Lab. Clin. Med. 1997 129 649 652
42. G. J. Brewer R. D. Dick V. D. Johnson J. A. Brunberg K. J. Kluin J. K. Fink Treatment of Wilson's disease with zinc: XV. long-term follow-up studies J. Lab. Clin. Med. 1998 132 264 278
43. G. J. Brewer V. D. Johnson R. D. Dick J. K. Fink K. J. Kluin P. Hedera Treatment of Wilson's disease with zinc: XVII. Treatment during pregnancy Hepatology 2000 31 364 370
44. G. J. Brewer R. D. Dick V. D. Johnson J. K. Fink K. J. Kluin S. Daniels Treatment of Wilson's disease with zinc: XVI. Treatment during the pediatric years J. Lab. Clin. Med. 2001 137 191 198
45. G. J. Brewer R. D. Dick V. Yuzbasiyan-Gurkan R. Tankanow A. B. Young K. J. Kluin Initial therapy of patients with Wilson's disease with tetrathiomolybdate Arch. Neurol. 1991 48 42 47
46. G. J. Brewer R. D. Dick V. Johnson Y. Wang V. Yuzbasiyan-Gurkan K. Kluin J. K. Fink A. Aisen Treatment of Wilson's disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients Arch. Neurol. 1994 51 545 554
47. G. J. Brewer V. Johnson R. D. Dick K. J. Kluin J. K. Fink J. A. Brunberg Treatment of Wilson disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy Arch. Neurol. 1996 53 1017 1025
48. G. J. Brewer P. Hedera K. J. Kluin M. Carlson F. Askari R. B. Dick J. Sitterly J. K. Fink Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy Arch. Neurol. 2003 60 379 385
49. E. M. Gartner K. A. Griffith Q. Pan G. J. Brewer G. F. Henja S. D. Merajver M. M. Zalupski A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer Invest. New Drugs 2008
50. N. L. Henry R. Dunn S. Merjaver P. Pan K. J. Pienta G. J. Brewer D. C. Smith Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone refractory prostate cancer Oncology 2006 71 168 175
51. B. G. Redman P. Esper Q. Pan R. L. Dunn H. K. Hussain T. Chenevert G. J. Brewer S. D. Merajver Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer Clin. Cancer Res. 2003 9 1666 1672
52. A. K. Vine G. J. Brewer Tetrathiomolybdate as an antiangiogenesis therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration Trans. Am. Ophthalmol. Soc. 2002 100 73 76
53. H. I. Pass G. J. Brewer R. Dick M. Carbone S. Merajver A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results Ann. Thorac. Surg. 2008 86 383 389
54. G. J. Brewer, F. Askari, M. T. Lorincz, M. Carlson, K. J. Kluin, J. K. Fink, R. B. Dick and J. Sitterly, Treatment of Wilson's Disease with Ammonium Tetrathiomolybdate: VI. New Dosage Regimen to Reduce Side Effects, unpublished work
55. M. Marcellini V. Di Ciommo F. Callea R. Devito D. Comparcola M. R. Sartorelli G. Carelli V. Nobili Treatment of Wilson's disease with zinc from the time of diagnosis in pediatric patients: a single-hospital, 10-year follow-up study J. Lab. Clin. Med. 2005 145 139 143
56. G. J. Brewer F. Askari R. Dick J. A. Sitterly J. K. Fink M. Carlson K. J. Kluin M. T. Lorincz The treatment of Wilson's disease with tetrathiomolybdate (TM): V. Control of free copper by TM and a comparison with trientine Transl. Res.
57. F. K. Askari J. Greenson R. D. Dick V. D. Johnson G. J. Brewer Treatment of Wilson's disease with zinc. XVIII. Initial treatment of the hepatic decompensation presentation with trientine and zinc J. Lab. Clin. Med. 2003 142 385 390
58. C. D. Cox T. N. Teknos M. Barrios G. J. Brewer R. D. Dick S. D. Merajver The role of copper suppression as an antiangiogenic strategy in head and neck squamous cell carcinoma Laryngoscope 2001 111 696 701
59. C. Cox S. D. Merajver S. Yoo R. D. Dick G. J. Brewer J. S. Lee T. N. Teknos Inhibition of the growth of squamous cell carcinoma by tetrathiomolybdate-induced copper suppression in a murine model Arch. Otolaryngol. Head Neck Surg. 2003 129 781 785
60. M. K. Khan M. W. Miller J. Taylor N. K. Gill R. D. Dick K. Van Golen G. J. Brewer S. D. Merajver Radiotherapy and antiangiogenic TM in lung cancer Neoplasia 2002 4 164 170
61. Q. Pan C. G. Kleer K. L. van Golen J. Irani K. M. Bottema C. Bias M. De Carvalho E. A. Mesri D. M. Robins R. D. Dick G. J. Brewer S. D. Merajver Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis Cancer Res. 2002 62 4854 4859
62. Q. Pan L. W. Bao C. G. Kleer G. J. Brewer S. D. Merajver Antiangiogenic tetrathiomolybdate enhances the efficacy of doxorubicin against breast carcinoma Mol. Cancer Ther. 2003 2 617 622
63. K. L. van Golen L. Bao G. J. Brewer K. J. Pienta J. M. Kamradt D. L. Livant S. D. Merajver Suppression of tumor recurrence and metastasis by a combination of the PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma Neoplasia 2002 4 373 379
64. G. J. Brewer M. R. Ullenbruch R. B. Dick L. Olivarez S. H. Phan Tetrathiomolybdate therapy protects against bleomycin-induced pulmonary fibrosis in mice J. Lab. Clin. Med. 2003 141 210 216
65. G. J. Brewer R. Dick M. R. Ullenbruch H. Jin S. H. Phan Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis J. Inorg. Biochem. 2004 98 2160 2167
66. F. K. Askari R. B. Dick M. Mao G. J. Brewer Tetrathiomolybdate therapy protects against concanavalin A and carbon tetrachloride hepatic damage in mice Exp. Biol. Med. 2004 229 857 863
67. M. Song Z. Song S. Barve J. Zhang T. Chen T. Liu G. E. Arteel G. J. Brewer C. J. McClain Tetrathiomolybdate protects against bile duct ligation-induced cholestatic liver injury and fibrosis J. Pharmacol. Exp. Ther. 2008 325 409 416
68. G. Hou R. Dick G. J. Brewer Improvement in dissolution of liver fibrosis in an animal model by tetrathiomolybdate Exp. Biol. Med.
69. S. Ma G. Hou R. D. Dick G. J. Brewer Tetrathiomolybdate protects against liver injury from acetaminophen in mice J. Appl. Res. Clin. Exp. Ther. 2004 4 419 426
70. G. Hou R. Dick G. D. Abrams G. J. Brewer Tetrathiomolybdate protects against cardiac damage by doxorubicin in mice J. Lab. Clin. Med. 2005 146 299 303
71. M. D. McCubbin G. Hou G. D. Abrams R. Dick Z. Zhang G. J. Brewer Tetrathiomolybdate is effective in a mouse model of arthritis J. Rheumatol. 2006 33 2501 2506
72. G. Hou G. Abrams R. Dick G. J. Brewer Efficacy of tetrathiomolybdate in a mouse model of multiple sclerosis Transl. Res. 2008 52 239 244
73. G. J. Brewer R. Dick C. Zeng G. Hou The use of tetrathiomolybdate in treating fibrotic, inflammatory, and autoimmune diseases, including the non-obese diabetic mouse model J. Inorg. Biochem. 2006 100 927 930
74. G. J. Brewer R. D. Dick D. K. Grover V. LeClaire M. Tseng M. Wicha K. Pienta B. G. Redman J. Thierry V. K. Sondak M. Strawderman G. LeCarpentier S. D. Merajver Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study Clin. Cancer Res. 2000 6 1 10
75. K. R. Flaherty, D. A. Arenberg, E. S. White, V. Thannickal, A. Andrei, S. Murray, T. V. Colby, W. D. Travis, E. A. Kazerooni, B. H. Gross, R. Paine, G. B. Toews, G. J. Brewer and F. J. Martinez, Treatment of Idiopathic Pulmonary Fibrosis with Tetrathiomolybdate, unpublished work
76. F. Askari D. Innis R. Dick G. Hou J. Marrero J. Greenson G. J. Brewer Treatment of primary biliary cirrhosis with tetrathiomolybdate: Results of a double blind trial Transl. Res.